JP5344924B2 - 臓器／四肢を保存するための組成物の用法 - Google Patents
臓器／四肢を保存するための組成物の用法 Download PDFInfo
- Publication number
- JP5344924B2 JP5344924B2 JP2008541642A JP2008541642A JP5344924B2 JP 5344924 B2 JP5344924 B2 JP 5344924B2 JP 2008541642 A JP2008541642 A JP 2008541642A JP 2008541642 A JP2008541642 A JP 2008541642A JP 5344924 B2 JP5344924 B2 JP 5344924B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- siloxane
- compound
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 88
- 210000000056 organ Anatomy 0.000 title claims description 42
- -1 alkane compound Chemical class 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 239000001301 oxygen Substances 0.000 claims description 30
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 29
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 28
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 229940087168 alpha tocopherol Drugs 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 229960000984 tocofersolan Drugs 0.000 claims description 5
- 239000002076 α-tocopherol Substances 0.000 claims description 5
- 235000004835 α-tocopherol Nutrition 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940108325 retinyl palmitate Drugs 0.000 claims description 3
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 3
- 239000011769 retinyl palmitate Substances 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 18
- 230000001954 sterilising effect Effects 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 14
- 229920002545 silicone oil Polymers 0.000 description 11
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 9
- 238000004321 preservation Methods 0.000 description 6
- WRYIIOKOQSICTB-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane Chemical compound CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F WRYIIOKOQSICTB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- DFUYAWQUODQGFF-UHFFFAOYSA-N 1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane Chemical compound CCOC(F)(F)C(F)(F)C(F)(F)C(F)(F)F DFUYAWQUODQGFF-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005055811.9 | 2005-11-23 | ||
| DE102005055811A DE102005055811A1 (de) | 2005-11-23 | 2005-11-23 | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| PCT/EP2006/011247 WO2007059968A2 (de) | 2005-11-23 | 2006-11-23 | Verwendung einer zusammensetzung zur konservierung von organen und gliedmassen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516717A JP2009516717A (ja) | 2009-04-23 |
| JP2009516717A5 JP2009516717A5 (https=) | 2012-10-04 |
| JP5344924B2 true JP5344924B2 (ja) | 2013-11-20 |
Family
ID=37965062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541642A Expired - Fee Related JP5344924B2 (ja) | 2005-11-23 | 2006-11-23 | 臓器／四肢を保存するための組成物の用法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8029977B2 (https=) |
| EP (1) | EP1956895B1 (https=) |
| JP (1) | JP5344924B2 (https=) |
| KR (1) | KR101058744B1 (https=) |
| CN (1) | CN101312647B (https=) |
| AT (1) | ATE509522T1 (https=) |
| AU (1) | AU2006316738B2 (https=) |
| BR (1) | BRPI0618805A2 (https=) |
| CA (1) | CA2628085C (https=) |
| DE (1) | DE102005055811A1 (https=) |
| DK (1) | DK1956895T3 (https=) |
| ES (1) | ES2365415T3 (https=) |
| IL (1) | IL191133A0 (https=) |
| NZ (1) | NZ568206A (https=) |
| WO (1) | WO2007059968A2 (https=) |
| ZA (1) | ZA200803599B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785656B1 (ko) * | 2007-05-14 | 2007-12-17 | 재단법인서울대학교산학협력재단 | 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체 |
| EP2110126B9 (de) * | 2008-04-18 | 2012-09-19 | Novaliq GmbH | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
| EP2335692A1 (en) * | 2009-12-04 | 2011-06-22 | AL.CHI.MI.A. S.r.l. | Silicone liquid and fluorinated liquid for sequential use in the treatment of retinal tears and/or detachments |
| WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CN107397718A (zh) | 2011-05-25 | 2017-11-28 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
| KR101989648B1 (ko) | 2012-01-23 | 2019-06-14 | 노바리크 게엠베하 | 부분불소화 알칸에 기초한 안정화된 단백질 조성물 |
| DK3181119T3 (da) | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| KR101284530B1 (ko) * | 2012-11-13 | 2013-07-16 | 공주대학교 산학협력단 | 생물학적 영구표본 제작용 치환제 및 이의 용도 |
| BR112016001522B1 (pt) | 2013-07-23 | 2019-10-01 | Novaliq Gmbh | Composições de anticorpo estabilizado |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| MX2018003781A (es) * | 2015-09-30 | 2018-09-12 | Novaliq Gmbh | Compuestos semifluorados para administracion oftalmica. |
| CN105248412A (zh) * | 2015-10-30 | 2016-01-20 | 暨南大学 | 一种乳化氟碳液在制备肺器官保存液中的应用 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| PT3399962T (pt) | 2016-12-23 | 2020-09-03 | Novaliq Gmbh | Composição oftálmica para o tratamento da doença do olho seco |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| KR102882058B1 (ko) | 2018-03-28 | 2025-11-07 | 노바리크 게엠베하 | 티몰롤을 포함하는 약제학적 조성물 |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| WO2020064556A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Topical sunscreen formulation |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0440925A1 (en) | 1989-12-13 | 1991-08-14 | The Green Cross Corporation | Internal organ-preserving liquid and method for preserving internal organs |
| FR2679150A1 (fr) * | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| DE4205341A1 (de) | 1992-02-21 | 1993-08-26 | Pharmpur Gmbh | Verfahren zur reinigung von perfluorcarbonen und verwendung der gereinigten perfluorcarbone |
| FR2716678B1 (fr) * | 1994-02-25 | 1996-05-15 | Opsia | Nouveaux composés organiques fluorés, applications en particulier ophtalmologiques et procédé de fabrication. |
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| JPH09157251A (ja) | 1995-10-06 | 1997-06-17 | Kanegafuchi Chem Ind Co Ltd | Ｎ−（Ｄ−α−メチル−β−メルカプトプロピオニル）−Ｌ−プロリン及び該中間体の製造方法 |
| US5952168A (en) * | 1996-11-07 | 1999-09-14 | 21St Century Medicine, Inc. | Method for vitrification of biological materials using alkoxylated compounds |
| US6475716B1 (en) * | 2001-03-06 | 2002-11-05 | Biobank Co., Ltd. | Method for preserving mammalian organs |
-
2005
- 2005-11-23 DE DE102005055811A patent/DE102005055811A1/de not_active Withdrawn
-
2006
- 2006-11-23 CA CA2628085A patent/CA2628085C/en not_active Expired - Fee Related
- 2006-11-23 JP JP2008541642A patent/JP5344924B2/ja not_active Expired - Fee Related
- 2006-11-23 US US12/094,951 patent/US8029977B2/en not_active Expired - Fee Related
- 2006-11-23 KR KR1020087013057A patent/KR101058744B1/ko not_active Expired - Fee Related
- 2006-11-23 EP EP06806724A patent/EP1956895B1/de not_active Not-in-force
- 2006-11-23 AU AU2006316738A patent/AU2006316738B2/en not_active Ceased
- 2006-11-23 DK DK06806724.8T patent/DK1956895T3/da active
- 2006-11-23 WO PCT/EP2006/011247 patent/WO2007059968A2/de not_active Ceased
- 2006-11-23 BR BRPI0618805-2A patent/BRPI0618805A2/pt not_active Application Discontinuation
- 2006-11-23 NZ NZ568206A patent/NZ568206A/en not_active IP Right Cessation
- 2006-11-23 ES ES06806724T patent/ES2365415T3/es active Active
- 2006-11-23 AT AT06806724T patent/ATE509522T1/de active
- 2006-11-23 CN CN2006800437943A patent/CN101312647B/zh not_active Expired - Fee Related
-
2008
- 2008-04-23 ZA ZA200803599A patent/ZA200803599B/xx unknown
- 2008-04-29 IL IL191133A patent/IL191133A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007059968A2 (de) | 2007-05-31 |
| CA2628085C (en) | 2013-06-04 |
| DK1956895T3 (da) | 2011-07-25 |
| EP1956895B1 (de) | 2011-05-18 |
| NZ568206A (en) | 2011-05-27 |
| ES2365415T3 (es) | 2011-10-04 |
| EP1956895A2 (de) | 2008-08-20 |
| ZA200803599B (en) | 2009-02-25 |
| AU2006316738A1 (en) | 2007-05-31 |
| US20090226875A1 (en) | 2009-09-10 |
| US8029977B2 (en) | 2011-10-04 |
| DE102005055811A1 (de) | 2007-05-31 |
| HK1126622A1 (en) | 2009-09-11 |
| CA2628085A1 (en) | 2007-05-31 |
| BRPI0618805A2 (pt) | 2011-09-13 |
| WO2007059968A3 (de) | 2008-07-10 |
| CN101312647B (zh) | 2012-06-27 |
| IL191133A0 (en) | 2008-12-29 |
| KR101058744B1 (ko) | 2011-08-24 |
| KR20080064998A (ko) | 2008-07-10 |
| AU2006316738B2 (en) | 2011-10-13 |
| CN101312647A (zh) | 2008-11-26 |
| ATE509522T1 (de) | 2011-06-15 |
| JP2009516717A (ja) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5344924B2 (ja) | 臓器／四肢を保存するための組成物の用法 | |
| US8642057B2 (en) | Antimicrobial and antiodor solutions and delivery systems | |
| KR20150103069A (ko) | 혈관 도관을 보존하기 위한 용액 | |
| CN105916374A (zh) | 用于增加器官和组织保存溶液的稳定性和储存寿命的溶液 | |
| HK1126622B (en) | Use of a composition for preserving organs and limbs | |
| MX2008006402A (en) | Use of a composition for preserving organs and members | |
| JP2016516830A (ja) | 酸素含有量が増加され、安定性が向上され、貯蔵寿命が長くなった臓器及び組織の保存溶液 | |
| TW201521577A (zh) | 用於增加器官及組織保存溶液之氧含量、安定性及保存壽命的含聚（０－２－羥乙基）澱粉調配物 | |
| WO2007043698A1 (ja) | 肝臓保存液 | |
| JP5011118B2 (ja) | インドメタシンを含有する外用液剤 | |
| US8846067B2 (en) | Antimicrobial solutions and methods | |
| TWI540961B (zh) | 具有增加安定性及儲存壽命的器官及組織保存調配物 | |
| TWI524843B (zh) | 保存血管導管之溶液 | |
| AU2013370276A1 (en) | Solution for preserving vascular conduits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090528 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120815 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120815 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130108 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130723 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130813 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |